Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
11 Aug, 20:00
NYSE NYSE
$
259. 80
-2.01
-0.7677%
$
620.77B Market Cap
29.06 P/E Ratio
0.69% Div Yield
3.65M Volume
9.91 Eps
$ 261.81
Previous Close
Add Transaction
Day Range
258.36 264.15
Year Range
171.81 274.9
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 7 months ago
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Reuters | 8 months ago
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

Seekingalpha | 8 months ago
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.

Zacks | 8 months ago
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now

5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now

For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.

247wallst | 8 months ago
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?

JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

Zacks | 8 months ago
3 Under-the-Radar Dividend Stocks Quietly Beating the Market

3 Under-the-Radar Dividend Stocks Quietly Beating the Market

For reasons that seem pretty obvious, dividend investors tend to chase the most familiar names like Pepsi (NYSE:PEP), Johnson and Johnson (NYSE:JNJ), and Procter & Gamble (NYSE:PG), and they do so for a lot of the right reasons.

247wallst | 8 months ago
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.

Zacks | 8 months ago
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.

Zacks | 8 months ago
The Dividend Stocks That Keep Paying Even When Markets Stumble

The Dividend Stocks That Keep Paying Even When Markets Stumble

When it comes to weathering market volatility, there is no easy answer, and what's worse is that when investors, retail or otherwise, try to time the market, it usually ends in disaster.

247wallst | 8 months ago
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Zacks | 8 months ago
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 8 months ago
Loading...
Load More